NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVBXXXX and the CUSIP is 63937X103. A total of 64 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $4,000 | -63.6% | 41,170 | -11.8% | 0.00% | – |
| Q3 2018 | $11,000 | -8.3% | 46,670 | -7.9% | 0.00% | -100.0% |
| Q2 2018 | $12,000 | -33.3% | 50,670 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $18,000 | 0.0% | 50,670 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $18,000 | -21.7% | 50,670 | -8.3% | 0.00% | 0.0% |
| Q3 2017 | $23,000 | -4.2% | 55,270 | +16.4% | 0.00% | 0.0% |
| Q2 2017 | $24,000 | -11.1% | 47,470 | 0.0% | 0.00% | -50.0% |
| Q1 2017 | $27,000 | -6.9% | 47,470 | +4.4% | 0.00% | 0.0% |
| Q4 2016 | $29,000 | -27.5% | 45,470 | +6.9% | 0.00% | -33.3% |
| Q1 2016 | $40,000 | -29.8% | 42,535 | 0.0% | 0.00% | -40.0% |
| Q4 2015 | $57,000 | -41.2% | 42,535 | 0.0% | 0.01% | -58.3% |
| Q3 2015 | $97,000 | +42.6% | 42,535 | 0.0% | 0.01% | +33.3% |
| Q2 2015 | $68,000 | 0.0% | 42,535 | 0.0% | 0.01% | +12.5% |
| Q1 2015 | $68,000 | -20.9% | 42,535 | -6.6% | 0.01% | -46.7% |
| Q4 2014 | $86,000 | +43.3% | 45,535 | 0.0% | 0.02% | +7.1% |
| Q3 2014 | $60,000 | -10.4% | 45,535 | 0.0% | 0.01% | -36.4% |
| Q2 2014 | $67,000 | – | 45,535 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Platinum Management (NY) LLC | 10,375,329 | $13,549,000 | 19.76% |
| Catalyst Capital Advisors LLC | 790,000 | $1,635,000 | 0.53% |
| DSC Advisors, L.P. | 500,000 | $1,035,000 | 0.50% |
| STONERIDGE INVESTMENT PARTNERS LLC | 142,528 | $295,000 | 0.06% |
| Hudock, Inc. | 30,500 | $63,000 | 0.05% |
| BRR OpCo, LLC | 52,700 | $109,000 | 0.05% |
| TFS CAPITAL LLC | 418,074 | $865,000 | 0.04% |
| LifePlan Financial Group, Inc | 28,810 | $60,000 | 0.04% |
| NOMURA HOLDINGS INC | 3,831,177 | $7,947,000 | 0.04% |
| BOLTON LP | 77,400 | $160,000 | 0.03% |